|
 |
European BioPharmaceutical Review
|
The completed sequencing of the human genome was a tremendous achievement but only 30 months later, the long-term knock on to the drug discovery industry is becoming apparent. The prediction is that by 2005 about half of all new products will come out of biotech; presumably this is why there are over 4,000 biotech-focused companies (approximately 10 per cent of which are public) out there.
Throughout these organisations computer-based research studies are increasing, and notably they are developing independently of the laboratory. Well-integrated information systems (IS) may one day develop into the primary R&D environment, with analytical laboratories reduced to a secondary role of investigative analysis and manufacturing. Consequently, I find myself wondering: how long before computer-based research overhauls traditional biological research and development?
Before I cause too much anxiety in the wet laboratory-based scientific community, let me elucidate what I mean by computer-based research. My view is that it includes, but is not restricted to, what many of you may already be thinking, namely the growing field of bioinformatics.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Line Clearance in Pharmaceutical Packaging & Manufacturing
5 February 2009, Manchester, UK
More info >>
|
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
